Patient mortality correlated with end-stage kidney disease quality incentive program facility payment reductions in “dose-response” and temporal patterns, according to a retrospective study.
Data published in the Clinical Journal of the American Society of Nephrology, revealed patients experienced higher mortality at each payment reduction level.
“While a mortality measure has not been included in the [End-Stage Renal Disease Quality Incentive Program] ESRD QIP to date, the ESRD QIP’s existing measures aim to capture aspects of facility quality of care that may impact